The incidence of thrombotic events with idarucizumab and andexanet alfa: A systematic review and meta-analysis

Direct thrombin inhibitor, dabigatran and factor Xa inhibitors, apixaban, edoxaban, and rivaroxaban (DOACs/NOACs), are currently the first-choice drugs in some indications. Life-threatening bleeding occurring during DOACs treatment may benefit from the use of reversal agents, however there are some...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Thrombosis research 2020-12, Vol.196, p.291-296
Hauptverfasser:	Rodrigues, André Oliveira, David, Cláudio, Ferreira, Joaquim J., Pinto, Fausto J., Costa, João, Caldeira, Daniel
Format:	Artikel
Sprache:	eng
Schlagworte:	DOAC antidotes Myocardial Infarction Reversal agents Stroke Undergoing surgery Venous thromboembolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!